# Role of Calcium Chloride Injection in Alleviating Atrial Fibrillation Post CABG

Study · id `cardio:ct-nct06378021` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06378021](<https://clinicaltrials.gov/study/NCT06378021>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06378021

Browse, organ or system: Heart  
Browse, condition area: Stroke; Heart rhythm problems  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 100 participants.

## Technical summary

Registry record NCT06378021. Randomized; no masking; primary purpose prevention. Start 2024-03-14 (actual); primary completion 2025-03 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 100 participants (planned count; ClinicalTrials.gov record NCT06378021, source copy `cardio:ctgov-nct06378021-2024-04-22`, retrieved 2026-10-26)
- Started: 2024-03-14 (actual) (ClinicalTrials.gov record NCT06378021, source copy `cardio:ctgov-nct06378021-2024-04-22`, retrieved 2026-10-26)
- Primary completion: 2025-03 (anticipated) (ClinicalTrials.gov record NCT06378021, source copy `cardio:ctgov-nct06378021-2024-04-22`, retrieved 2026-10-26)
- Completion: 2025-04 (anticipated) (ClinicalTrials.gov record NCT06378021, source copy `cardio:ctgov-nct06378021-2024-04-22`, retrieved 2026-10-26)
- Countries: Egypt (ClinicalTrials.gov record NCT06378021, source copy `cardio:ctgov-nct06378021-2024-04-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06378021-2024-04-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: Role of Calcium Chloride Injection in Alleviating Atrial Fibrillation Post CABG
- Condition: Atrial Fibrillation
- Intervention (Drug): Calcium Chloride
- Intervention (Drug): Sodium Chloride 0.9% Inj
- Lead sponsor: Helwan University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Arrhythmia (heart rhythm problems) (`cardio:arrhythmia`)
- Registry condition terms include this condition: Atrial fibrillation (AF) (`cardio:atrial-fibrillation`)
- Registry lists this organization as the lead sponsor: Helwan University (`cardio:org-helwan-university`)

## Provenance

Content hash: f51dc0fabbee75cc89c5405cd5bcda574267e9a2393c1b746cfb5c9d40c79350
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
